Clinical TrialMay 14, 2026, 07:32 AM
BriaCell Completes Bria-PROS+ Manufacturing; Phase 1/2a Study Soon
AI Summary
BriaCell Therapeutics has completed manufacturing clinical supplies of Bria-PROS+, its next-generation personalized off-the-shelf immunotherapy for prostate cancer. The company plans to initiate a Phase 1/2a clinical study for Bria-PROS+ in the coming months, supported by a $2 million non-dilutive grant from the US National Cancer Institute. Preclinical data demonstrated that Bria-PROS+ activated both adaptive and innate immunity, supporting its further clinical evaluation. This candidate builds on the Bria-OTS+ platform, which also underpins Bria-BRES+, a breast cancer immunotherapy that recently received FDA IND clearance.
Key Highlights
- BriaCell completed manufacturing clinical supplies of Bria-PROS+ for prostate cancer.
- Company plans to initiate a Phase 1/2a clinical study for Bria-PROS+ in coming months.
- Received a $2 million non-dilutive grant from US NCI in August 2025 for Bria-PROS+.
- Preclinical data showed Bria-PROS+ activated T-cells, dendritic cells, and NK cells.
- Bria-PROS+ is based on the Bria-OTS+ platform, similar to Bria-BRES+.
- Bria-BRES+ recently received FDA Investigational New Drug (IND) application clearance.
- Bria-OTS program saw a patient achieve 100% resolution of a lung metastasis.
Price Impact
More from BCTX